470 related articles for article (PubMed ID: 27220749)
1. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer.
Chen L; Cook LS; Tang MT; Porter PL; Hill DA; Wiggins CL; Li CI
Breast Cancer Res Treat; 2016 Jun; 157(3):545-54. PubMed ID: 27220749
[TBL] [Abstract][Full Text] [Related]
2. Reproductive Factors and Risk of Luminal, HER2-Overexpressing, and Triple-Negative Breast Cancer Among Multiethnic Women.
Chen L; Li CI; Tang MT; Porter P; Hill DA; Wiggins CL; Cook LS
Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1297-304. PubMed ID: 27307466
[TBL] [Abstract][Full Text] [Related]
3. Alcohol, smoking, and risk of Her2-overexpressing and triple-negative breast cancer relative to estrogen receptor-positive breast cancer.
Baglia ML; Cook LS; Mei-Tzu C; Wiggins C; Hill D; Porter P; Li CI
Int J Cancer; 2018 Oct; 143(8):1849-1857. PubMed ID: 29708591
[TBL] [Abstract][Full Text] [Related]
4. Body mass index at age 18 years and recent body mass index in relation to risk of breast cancer overall and ER/PR/HER2-defined subtypes in white women and African-American women: a pooled analysis.
Ma H; Ursin G; Xu X; Lee E; Togawa K; Malone KE; Marchbanks PA; McDonald JA; Simon MS; Folger SG; Lu Y; Sullivan-Halley J; Deapen DM; Press MF; Bernstein L
Breast Cancer Res; 2018 Jan; 20(1):5. PubMed ID: 29357906
[TBL] [Abstract][Full Text] [Related]
5. Recent Use of Oral Contraceptives and Risk of Luminal B, Triple-Negative, and HER2-Overexpressing Breast Cancer.
Lorona NC; Cook LS; Tang MC; Hill DA; Wiggins CL; Li CI
Horm Cancer; 2019 Jun; 10(2-3):71-76. PubMed ID: 30989580
[TBL] [Abstract][Full Text] [Related]
6. Reproductive characteristics, menopausal status, race and ethnicity, and risk of breast cancer subtypes defined by ER, PR and HER2 status: the Breast Cancer Etiology in Minorities study.
John EM; Koo J; Phipps AI; Longacre TA; Kurian AW; Ingles SA; Wu AH; Hines LM
Breast Cancer Res; 2024 May; 26(1):88. PubMed ID: 38822357
[TBL] [Abstract][Full Text] [Related]
7. Height, body mass index (BMI), BMI change, and the risk of estrogen receptor-positive, HER2-positive, and triple-negative breast cancer among women ages 20 to 44 years.
Kawai M; Malone KE; Tang MT; Li CI
Cancer; 2014 May; 120(10):1548-56. PubMed ID: 24500704
[TBL] [Abstract][Full Text] [Related]
8. Association between common risk factors and molecular subtypes in breast cancer patients.
Turkoz FP; Solak M; Petekkaya I; Keskin O; Kertmen N; Sarici F; Arik Z; Babacan T; Ozisik Y; Altundag K
Breast; 2013 Jun; 22(3):344-50. PubMed ID: 22981738
[TBL] [Abstract][Full Text] [Related]
9. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.
Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H
Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840
[TBL] [Abstract][Full Text] [Related]
10. Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil.
Carvalho FM; Bacchi LM; Pincerato KM; Van de Rijn M; Bacchi CE
BMC Womens Health; 2014 Aug; 14():102. PubMed ID: 25174527
[TBL] [Abstract][Full Text] [Related]
11. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
Carey LA; Perou CM; Livasy CA; Dressler LG; Cowan D; Conway K; Karaca G; Troester MA; Tse CK; Edmiston S; Deming SL; Geradts J; Cheang MC; Nielsen TO; Moorman PG; Earp HS; Millikan RC
JAMA; 2006 Jun; 295(21):2492-502. PubMed ID: 16757721
[TBL] [Abstract][Full Text] [Related]
12. A pooled case-only analysis of obesity and breast cancer subtype among Black women in the southeastern United States.
Moore J; Pal T; Beeghly-Fadiel A; Fadden MK; Munro HM; Dujon SA; Reid S; Tezak A; Blasingame M; Ware J; Blot WJ; Shu XO; Zheng W; Sanderson M; Lipworth L
Cancer Causes Control; 2022 Apr; 33(4):515-524. PubMed ID: 35088206
[TBL] [Abstract][Full Text] [Related]
13. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.
Ihemelandu CU; Leffall LD; Dewitty RL; Naab TJ; Mezghebe HM; Makambi KH; Adams-Campbell L; Frederick WA
J Surg Res; 2007 Nov; 143(1):109-18. PubMed ID: 17950079
[TBL] [Abstract][Full Text] [Related]
14. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.
Ellingjord-Dale M; Vos L; Tretli S; Hofvind S; Dos-Santos-Silva I; Ursin G
Breast Cancer Res; 2017 Jan; 19(1):10. PubMed ID: 28114999
[TBL] [Abstract][Full Text] [Related]
15. Relationship of established risk factors with breast cancer subtypes.
McCarthy AM; Friebel-Klingner T; Ehsan S; He W; Welch M; Chen J; Kontos D; Domchek SM; Conant EF; Semine A; Hughes K; Bardia A; Lehman C; Armstrong K
Cancer Med; 2021 Sep; 10(18):6456-6467. PubMed ID: 34464510
[TBL] [Abstract][Full Text] [Related]
16. Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California.
Parise C; Caggiano V
Cancer Epidemiol; 2014 Oct; 38(5):556-62. PubMed ID: 25172158
[TBL] [Abstract][Full Text] [Related]
17. Obesity, body fat distribution, and risk of breast cancer subtypes in African American women participating in the AMBER Consortium.
Bandera EV; Chandran U; Hong CC; Troester MA; Bethea TN; Adams-Campbell LL; Haiman CA; Park SY; Olshan AF; Ambrosone CB; Palmer JR; Rosenberg L
Breast Cancer Res Treat; 2015 Apr; 150(3):655-66. PubMed ID: 25809092
[TBL] [Abstract][Full Text] [Related]
18. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies.
Yang XR; Chang-Claude J; Goode EL; Couch FJ; Nevanlinna H; Milne RL; Gaudet M; Schmidt MK; Broeks A; Cox A; Fasching PA; Hein R; Spurdle AB; Blows F; Driver K; Flesch-Janys D; Heinz J; Sinn P; Vrieling A; Heikkinen T; Aittomäki K; Heikkilä P; Blomqvist C; Lissowska J; Peplonska B; Chanock S; Figueroa J; Brinton L; Hall P; Czene K; Humphreys K; Darabi H; Liu J; Van 't Veer LJ; van Leeuwen FE; Andrulis IL; Glendon G; Knight JA; Mulligan AM; O'Malley FP; Weerasooriya N; John EM; Beckmann MW; Hartmann A; Weihbrecht SB; Wachter DL; Jud SM; Loehberg CR; Baglietto L; English DR; Giles GG; McLean CA; Severi G; Lambrechts D; Vandorpe T; Weltens C; Paridaens R; Smeets A; Neven P; Wildiers H; Wang X; Olson JE; Cafourek V; Fredericksen Z; Kosel M; Vachon C; Cramp HE; Connley D; Cross SS; Balasubramanian SP; Reed MW; Dörk T; Bremer M; Meyer A; Karstens JH; Ay A; Park-Simon TW; Hillemanns P; Arias Pérez JI; Menéndez Rodríguez P; Zamora P; Benítez J; Ko YD; Fischer HP; Hamann U; Pesch B; Brüning T; Justenhoven C; Brauch H; Eccles DM; Tapper WJ; Gerty SM; Sawyer EJ; Tomlinson IP; Jones A; Kerin M; Miller N; McInerney N; Anton-Culver H; Ziogas A; Shen CY; Hsiung CN; Wu PE; Yang SL; Yu JC; Chen ST; Hsu GC; Haiman CA; Henderson BE; Le Marchand L; Kolonel LN; Lindblom A; Margolin S; Jakubowska A; Lubiński J; Huzarski T; Byrski T; Górski B; Gronwald J; Hooning MJ; Hollestelle A; van den Ouweland AM; Jager A; Kriege M; Tilanus-Linthorst MM; Collée M; Wang-Gohrke S; Pylkäs K; Jukkola-Vuorinen A; Mononen K; Grip M; Hirvikoski P; Winqvist R; Mannermaa A; Kosma VM; Kauppinen J; Kataja V; Auvinen P; Soini Y; Sironen R; Bojesen SE; Ørsted DD; Kaur-Knudsen D; Flyger H; Nordestgaard BG; Holland H; Chenevix-Trench G; Manoukian S; Barile M; Radice P; Hankinson SE; Hunter DJ; Tamimi R; Sangrajrang S; Brennan P; McKay J; Odefrey F; Gaborieau V; Devilee P; Huijts PE; Tollenaar RA; Seynaeve C; Dite GS; Apicella C; Hopper JL; Hammet F; Tsimiklis H; Smith LD; Southey MC; Humphreys MK; Easton D; Pharoah P; Sherman ME; Garcia-Closas M
J Natl Cancer Inst; 2011 Feb; 103(3):250-63. PubMed ID: 21191117
[TBL] [Abstract][Full Text] [Related]
19. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004.
Brown M; Tsodikov A; Bauer KR; Parise CA; Caggiano V
Cancer; 2008 Feb; 112(4):737-47. PubMed ID: 18189290
[TBL] [Abstract][Full Text] [Related]
20. Hypothesized role of pregnancy hormones on HER2+ breast tumor development.
Cruz GI; Martínez ME; Natarajan L; Wertheim BC; Gago-Dominguez M; Bondy M; Daneri-Navarro A; Meza-Montenegro MM; Gutierrez-Millan LE; Brewster A; Schedin P; Komenaka IK; Castelao JE; Carracedo A; Redondo CM; Thompson PA
Breast Cancer Res Treat; 2013 Jan; 137(1):237-46. PubMed ID: 23135573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
